Tonix reports Q4 2025 net loss $46.9M; TONMYA launch shows ~4,200 prescriptions

Tonix Pharmaceuticals Holding Corp.

Net loss available to common stockholders for Q4 2025 was $46.9M ($3.98/share) vs $22.1M ($9.77/share) in Q4 2024.
Full year 2025 net product revenue $13.1M, including TONMYA launch from Nov 17–Dec 31: $1.4M.
TONMYA launch-to-date (Nov 17,2025–Feb 27,2026): >1,500 HCPs prescribed, ~2,500 patients initiated, ~4,200 cumulative prescriptions.
Cash and equivalents $207.6M as of Dec 31, 2025 (up from $98.8M); subsequent ATM raised $8.6M.
Cash runway expected into Q1 2027; shares outstanding 13.4M as of March 11, 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

announced its operating results for the quarter and year ended December 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-26-005742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.